The INN assignment is a non-material administrative milestone. The real catalysts are BASECAMP enrollment completion (imminent) and Phase 2 data release (Q4 2026). Monitor for those events; the naming itself does not change the investment thesis.
Price Chart
Executive Summary
Satellos announced the WHO-assigned International Nonproprietary Name (INN) 'forazapadin' for its lead Duchenne muscular dystrophy drug candidate, previously known as SAT-3247. The naming is a routine regulatory milestone that signals program maturity but provides no new clinical data or financial information. The filing also reiterates expected BASECAMP enrollment completion this quarter and Phase 2 data release in Q4 2026, which are the key upcoming catalysts.
Key Facts
- INN 'forazapadin' assigned by WHO for lead candidate SAT-3247
- BASECAMP enrollment completion expected this quarter (Q3 2026)
- BASECAMP clinical data expected in Q4 2026
- Phase 2 trial in FSHD planned to begin by end of 2026
- Cash runway expected through 2027
Financial Impact
No financial figures disclosed; naming milestone has no direct revenue or cost impact
Risk Factors
- No clinical data released — all forward-looking statements about trial timelines and regulatory submissions are subject to delay or failure
- Cash runway through 2027 depends on no unexpected cost overruns or delays
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001171843-26-005936 |
| Document: f6k_090826.htm | 0001171843-26-005936 |
| Document: 0001171843-26-005936-index-headers.html | 0001171843-26-005936 |
| Document: 0001171843-26-005936-index.html | 0001171843-26-005936 |
| Document: 0001171843-26-005936.txt | 0001171843-26-005936 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 21, 2026 5d ago | 6-K | $6.70 | awaiting T+20 | — | $6.54 (−2.39%) |
Oct 5, 2026 21d ago | 6-K | $8.05 | awaiting T+20 | — | $6.54 (−18.76%) |
Sep 30, 2026 26d ago | 6-K | $8.50 | awaiting T+20 | — | $6.54 (−23.06%) |
Sep 30, 2026 26d ago | Press Release | $8.50 | awaiting T+20 | — | $6.54 (−23.06%) |
Sep 24, 2026 4w ago | 6-K | $8.71 $6.63 | ▼ −23.94% | ▼ −23.52% | $6.54 (−24.91%) |
Sep 24, 2026 4w ago | Press Release | $8.71 $6.63 | ▼ −23.94% | ▼ −23.52% | $6.54 (−24.91%) |
Sep 15, 2026 5w ago | 6-K | $9.36 $7.04 | ▼ −24.79% | ▼ −27.51% | $6.54 (−30.13%) |
Sep 9, 2026 6w ago | 6-K | $10.02 $7.63 | ▼ −23.85% | ▼ −26.05% | $6.54 (−34.73%) |
Sep 1, 2026 7w ago | 6-K | $9.08 $8.69 | ▼ −4.30% | ▼ −5.48% | $6.54 (−27.97%) |
Aug 13, 2026 10w ago | 6-K | $9.61 $9.79 | ▲ +1.87% | ▲ +3.86% | $6.54 (−31.95%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers